Date: September 25, 2026

Board Meeting Outcomes

  • RPG Active Pharma Limited (RPGAP), a subsidiary of RPG Life Sciences Limited, held its Board meeting on September 25, 2026
  • Board approved Scheme of Amalgamation of Actis Generics Private Limited (wholly-owned subsidiary) with RPG Active Pharma Limited under Sections 230-232 of Companies Act, 2013

Scheme Details

Companies Involved:

  • Transferor Company: Actis Generics Private Limited
  • Transferee Company: RPG Active Pharma Limited

Financial Metrics (as of March 31, 2026):

  • RPG Active Pharma Limited: Net worth - INR 34.75 Crore, No revenue from operations (incorporated December 24, 2025)
  • Actis Generics Private Limited: Net worth - INR 34.60 Crore, Revenue from operations - INR 45.96 Crore (FY 2025-26)

Business Areas:

  • Actis Generics: Manufacturing of pharmaceutical, medical chemicals and botanical products
  • RPG Active Pharma: Manufacturing and marketing of active pharmaceutical ingredients

Rationale for Amalgamation

  • Streamlining corporate structure and consolidation of assets and liabilities
  • More efficient utilization of capital for enhanced development and growth
  • Simplified compliance structure and easier implementation of corporate actions
  • Improved management oversight and operational efficiencies
  • Cost savings through legal entity rationalization and elimination of duplicate expenses
  • Better business synergy in semi-conductor market in India

Transaction Structure

  • No cash consideration or share exchange ratio involved
  • No issuance of shares as consideration (Actis Generics is wholly-owned subsidiary)
  • Upon Scheme effectiveness, all shares of Transferor Company held by Transferee Company shall stand cancelled

Regulatory Aspects

  • Scheme subject to approvals from National Company Law Tribunal, shareholders of both companies, and other required authorities
  • Transaction classified as related party transaction but exempt from Section 188 requirements per MCA Circular No. 30/2014 dated July 17, 2014
  • No change in RPG Life Sciences Limited shareholding pattern post-amalgamation

Compliance Reference

  • Disclosure made pursuant to SEBI Master Circular No. HO/49/14/14(7)2025-CFD POD2/I/3762/2026 dated January 30, 2026